Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within thirty (30) days after receipt of an invoice from Codexis, Shell shall reimburse Codexis for a portion of the costs of (a) filing, prosecuting, responding to opposition and maintaining patent applications and patents in countries where Shell requests that patent applications be filed, prosecuted and maintained, and (b) filing, prosecuting, and responding to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings against the grant of letters patent owned by Third Parties that may limit the ability of the Parties to exploit the Program Technology. Such reimbursement shall equal fifty percent (50%) of such costs actually incurred in the United States, Europe, Argentina, Australia, Brazil, China, India, Japan, Singapore, South Korea and Turkey, and one hundred percent (100%) of such costs elsewhere, and in each case, shall be in addition to payments under Article 3. However, Shell may, upon sixty (60) days notice, request that Codexis discontinue filing or prosecution of patent applications in any country and shall have no obligation after the effective date of such notice to reimburse Codexis for the costs of filing, prosecuting, responding to opposition or maintaining such patent application or patent in such country. Codexis shall pay all costs in those countries in which Shell does not request that Codexis file, prosecute or maintain patent applications and patents, but in which Codexis, at its option, elects to do so.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Subject to Section 4.1.3, within thirty (30) days of receipt of invoices from Optosonics, Endra shall reimburse Optosonics for all the costs of filing, prosecuting, responding to opposition and maintaining patent applications and patents in countries where Endra requests that patent applications be filed, prosecuted and maintained. However, Endra may, upon sixty (60) days notice, request that Optosonics discontinue filing or prosecution of patent applications in any country and discontinue reimbursing Optosonics for the costs of filing, prosecuting, responding to opposition or maintaining such patent application or patent in any country. Optosonics shall pay all costs in those countries in which Endra does not request that Optosonics file, prosecute or maintain patent applications and patents, (or in which Endra requests such protection be discontinued) but in which Optosonics, at its option, elects to do so and Endra shall have no license in each of such countries and all licenses of Endra theretofore in existence under this Agreement in any such country shall forthwith terminate.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. (a) As between Codexis and IE, Codexis shall pay any and all costs and expenses in connection with the preparation, filing, prosecution and maintenance of Patent Rights within the Codexis Research Technology.
(b) As between Codexis and IE, IE shall pay any and all costs and expenses in connection with the preparation, filing, prosecution and maintenance of Patent Rights within the IE Research Technology.
(c) As between Codexis and IE, Codexis and IE shall jointly and equally pay any and all reasonable costs and expenses in connection with the preparation, filing, prosecution and maintenance of Patent Rights within the Jointly Owned Research Technology.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights where Pfizer requests that patent applications be filed, prosecuted and maintained. Such reimbursement shall be in addition to Funding Payments. However, Pfizer may, upon sixty (60) days notice, request that Myco discontinue filing or prosecution of patent applications in any country and discontinue reimbursing Myco for the costs of filing, prosecuting, responding to opposition and the like or maintaining such patent application or patent in any country. Myco shall pay all costs in those countries in which Pfizer does not request that Myco file, prosecute or maintain patent applications and patents, but in which Myco, at its option, elects to do so.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within thirty (30) days of receipt of invoices from Mitokor, Pfizer shall reimburse Mitokor for all the costs of filing, prosecuting, responding to opposition and maintaining patent applications and patents in countries where Pfizer consents to or requests that patent applications be filed, prosecuted and maintained. Such reimbursement shall be in addition to other funding payments under this Agreement and shall include such costs of all activities described in 7.1 (a)-(e) above. However, Pfizer may, upon sixty (60) days notice, request that Mitokor discontinue filing or prosecution of patent applications in any country and discontinue reimbursing Mitokor for the costs of filing, prosecuting, responding to opposition or maintaining such patent application or patent in any country. Mitokor shall pay all costs in those countries in which Pfizer requests that Mitokor not file, prosecute or maintain patent applications and patents, but in which Mitokor, at its option, elects to do so.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. At least ninety (90) days prior to a patent filing deadline, Pfizer will notify Isis in writing of those countries in which Pfizer requests the [***]be filed, prosecuted and maintained. Within [***] ([***]) days of receipt of invoices from Isis, Pfizer shall reimburse Isis for all the costs of filing, prosecuting, responding to opposition and maintaining the [***]in countries where Pfizer requests that the [***] be filed, prosecuted and/or maintained, including costs incurred prior to the Effective Date. Such reimbursement shall be in addition to payments under Section 3. However, Pfizer may, upon [***] ([***]) days notice, request that Isis discontinue the filing, prosecution or maintenance of the Isis [***] in any country and discontinue reimbursing Isis for the costs of filing, prosecuting, responding to opposition or maintaining the [***] in such
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within thirty (30) days of receipt of invoices from Guilford, Pfizer shall reimburse Guilford for all the costs of filing, prosecuting, responding to opposition or other interested parties proceedings and maintaining patent applications and patents during the term of this Agreement. Such reimbursement shall be in addition to other funding payments under this Agreement and shall include such costs of all activities described in Section 8.1 (a)-(e) above. However, Pfizer may, upon sixty (60) days notice, request that Guilford discontinue filing or prosecution of patent applications in any country (other than the countries listed in Schedule 8.1.2) and discontinue reimbursing Guilford for the costs of filing, prosecuting, responding to opposition or maintaining such patent application or patent in any such country (other than the countries listed in Schedule 8.1.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within thirty (30) days of receipt of invoices from Gensia, Pfizer shall reimburse Gensia for all the costs of filing, prosecuting, responding to
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within [**] days of receipt of invoices from Icagen, Pfizer shall reimburse Icagen for all the costs of Icagen’s performance of the duties set forth in Section 7.1 with respect to patent applications and patents in countries where Pfizer requests that patent applications and patents be filed, prosecuted and maintained except that in the event Pfizer objects to Icagen’s choice of patent counsel in Section 7.1(b) in good faith, including provision of legal services at reasonable fees consistent with Pfizer practice, and after considering Pfizer’s views Icagen selects such patent counsel, Pfizer shall only be obliged to reimburse [**] percent ([**]%) of the costs incurred by Icagen in using such patent counsel. Such reimbursement shall be in addition to payments under Section 4. However, Pfizer may, upon [**] days notice, request that Icagen discontinue the performance of duties set forth in Section 7.1 with respect to given patent applications and patents in any country. Icagen shall pay the costs of Icagen’s performance of the duties set forth in Section 7.1 in those countries in which Pfizer does not request that Icagen perform such duties, but in which Icagen, at its option, elects to do so; provided that if Pfizer elects not to pay for Icagen’s performance of the duties set forth in Section 7.1, with respect to patent applications and patents in any country, such patent applications and patents shall be solely owned by Icagen and shall be excluded from the Icagen Patent Rights and Pfizer’s licenses thereunder.
Reimbursement of Costs for Filing, Prosecuting and Maintaining Patent Rights. Within thirty (30) days of receipt of invoices from Microcide, Pfizer shall reimburse Microcide for all the costs of filing, prosecuting, responding to opposition and maintaining patent applications and patents in countries where Pfizer requests that patent applications be filed, prosecuted and maintained. Such reimbursement shall be in addition to Funding Payments. However, Pfizer may, upon sixty (60) days notice, request that Microcide discontinue filing or prosecution of patent applications in any country and discontinue reimbursing Microcide for the costs of filing, prosecuting, responding to opposition or maintaining such patent application or patent in any country. Microcide shall pay all costs in those countries in which Pfizer does not request that Microcide file, prosecute or maintain patent applications and patents, but in which Microcide, at its option, elects to do so.
